Novo Nordisk A/S (NVO)
| Market Cap | 293.18B |
| Revenue (ttm) | 40.31B |
| Net Income (ttm) | 14.02B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.14 |
| PE Ratio | 21.15 |
| Forward PE | 16.03 |
| Dividend | $1.61 (2.43%) |
| Ex-Dividend Date | Mar 31, 2025 |
| Volume | 9,219,724 |
| Open | 66.39 |
| Previous Close | 65.16 |
| Day's Range | 65.41 - 66.64 |
| 52-Week Range | 57.00 - 148.15 |
| Beta | 0.25 |
| Analysts | Strong Buy |
| Price Target | 128.00 (+92.63%) |
| Earnings Date | May 7, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $128.0, which is an increase of 92.63% from the latest price.
News
Hims & Hers stock price soars after partnership with Novo Nordisk to offer weight-loss drug Wegovy
Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo Nordi...
Why New Wegovy Deals Won't Restore Novo Nordisk's Obesity Lead
The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only getting wider.
Growth Is Priced Out Of Novo Nordisk
A lot went wrong for Novo Nordisk A/S in the last six months, and a lot went right for competitor Eli Lilly. Novo Nordisk's competitive positioning in the obesity market has worsened, but I believe th...
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Novo Nordisk A/S NVO and Hims & Hers Health, Inc. HIMS announced a long-term collaboration on Tuesday.
Pharma firms maastraz
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
Hims & Hers partners with Novo Nordisk to sell Wegovy
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
Hims & Hers Health, Inc. just announced a partnership with Novo Nordisk, Ro and LifeMD to sell their Wegovy at a discounted price. The deal is a game changer, enabling Hims to offer Wegovy at $599/mon...
White House Slams AMZN, HIMS & NVO Wegovy Partnership, SOFI Rallies
Amazon (AMZN) shares faced selling pressure after the White House called the company's decision to display tariff costs on products a "hostile and political act." Diane King Hall notes it's just the l...
Hims & Hers to Sell Novo Nordisk's Wegovy in U.S., Shares Soar
Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.
Hims & Hers Health (HIMS) stock surges 34% on partnership with Novo Nordisk to sell Wegovy
Shares of Hims & Hers Health soared more than 34% in premarket trading on Tuesday after Novo Nordisk announced a partnership with the telehealth company to expand access to its popular weight loss dru...
Hims & Hers' stock rockets after teaming up with its rival Wegovy maker
Health and wellness company Hims & Hers, which sells alternatives to weight-loss drugs like Wegovy, is now collaborating with the maker of Wegovy.
Hims & Hers Stock Soars 45%. Why a Deal With Novo Nordisk for Weight-Loss Drugs Matters.
The companies announced a long-term collaboration to make obesity treatments more affordable, they said on Tuesday.
Novo Nordisk opens weight loss drug Wegovy to Hims & Hers, Ro and Life MD telehealth
Novo Nordisk said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and Life MD. The Danish drugmaker is racing to capture more patients now that many comp...
Hims & Hers partners with Novo Nordisk to sell Wegovy on its platform
Danish drugmaker Novo Nordisk has partnered with Hims & Hers Health's to sell its popular weight loss drug through a bundled offering on the telehealth company's platform, the two companies said on Tu...
Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care
SAN FRANCISCO--(BUSINESS WIRE)--Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven obesity care and treatments more accessible, mo...
Novo Nordisk's obesity drug Wegovy debuts in Thailand
Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's local subsidiary said on Monday, marking the injectable drug's first entry into...
How Eli Lilly and Novo Nordisk have separated themselves from their rivals
Most companies are likely going to feel the impact of President Trump's tariffs. In the video above, BofA Securities senior pharma & biotech analyst Tim Anderson describes how tariffs will impact the ...
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, unapproved versions of the drugmaker's blockbuster weight loss drug Wegovy and...
Ozempic copies restricted after US judge denies injunction
A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge over drug sh...
Novo Nordisk's stellar Wegovy-fuelled run of hiking sales guidance could be ending
Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year.
Chart Master: Sell Morgan Stanley, buy Novo Nordisk?
Carter Worth, Worth Charting, talks technicals on Morgan Stanley and Novo Nordisk.
Novo Nordisk: Be Greedy When Others Are Fearful
Novo Nordisk is a high-quality biopharma company with a strong diabetes franchise and a booming obesity drug segment, making it an attractive growth play. Following a 50% drop from recent highs, NVO t...
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill
Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots.
Is Novo Nordisk falling behind Eli Lilly in the weight-loss drug race?
Danish drugmaker Novo Nordisk A/S (CPH: NOVO-B) lost more than 10% last week after its US rival Eli Lilly & Co (NYSE: LLY) reported encouraging Phase 3 data for its oral weight-loss treatment. Lilly'...
5 European stocks to watch this earnings season as Trump's tariffs hit
The scale of President Donald Trump's tariffs, along with the volatility injected by subsequent updates and reversals in policy, have so far exceeded even the most bearish forecasts. Danish shipping g...